Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 591-597    DOI: 10.31083/j.ejgo.2020.04.4932
Original Research Previous articles | Next articles
Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?
Fengmei Wang1, , Huachun Luo2, , Huihua Cheng2, Huijuan Huang1, Zhichao Fu 2, *()
1Department of Obstetrics and Gynecology, Fuzhou General Hospital of PLA (Xiamen Dongfang Hospital), Fuzhou, Fujian Province, P. R. China
2Department of Radiation Oncology, Fuzhou General Hospital of PLA (Xiamen Dongfang Hospital), Fuzhou, Fujian Province, P. R. China
Download:  PDF(768KB)  ( 304 ) Full text   ( 13 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To investigate the guidance value of 3D printing in brachytherapy for cervical cancer and its role in the doctor-patient communication. Results: The median follow-up time was 36 months (10-63); 3D models of 50 patients with cervical cancer were successfully printed out. Fifty patients underwent 255 times the source applicator. EQD 2 of HR-CTV D90, bladder D2cc, sigmoid colon D2cc, and rectal D2cc were 75.26 ± 6.31, 67.84 ± 8.75, 47.36 ± 7.62, and 62.45 ± 8.68 Gy, respectively, and the overall score of the verisimilitude and usefulness of 3D printing models by five doctors was 8.0 ± 0.8 points. The score of patients' satisfaction to the use of 3D printing model for operation communication was 9.0 ± 0.5 points. During three months of follow-up, two patients were with rectal hemorrhage in later period (level 2), and the symptoms were improved after hemostasis, enema and other symptomatic treatments. Three-year local control (LC) was 92% (46/50), three-year progression-free survival (PFS) was 82% (41/50), and three-year overall survival (OS) was 84%. Three-year late toxic and side effects mainly include radiation proctitis, radiation urethritis, and vaginitis, and their level 3 incidence rates were: radiation gastroenteritis 10%, radiation urethritis 6%, and radiation vaginitis 1: 8%, respectively. Conclusion: 3D printing model can well display relationship with the surrounding normal tissues and effectively guide doctors to conduct individualized brachytherapy for cervical cancer. It can also be used as a tool to communicate with patients, render doctor-patient communication more effective, and obtain a good curative effect and less toxic and adverse effects, which is worth further clinical practice.
Key words:  3D-printing      Cervical cancer      Brachytherapy     
Submitted:  10 July 2018      Accepted:  30 October 2018      Published:  15 August 2020     
Fund: 
2017J01222/the Natural Science Foundation of Fujian Province
*Corresponding Author(s):  ZHI-CHAO FU     E-mail:  fauster1112@126.com
About author:  Contributed equally

Cite this article: 

Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.4932     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/591

[1] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[2] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[3] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[4] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[5] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[6] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[7] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[8] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[9] B. Bárány, R. Póka. Nutritional assessment among patients with cervical cancer and controls[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 23-29.
[10] D. Kim, Y. Ki, W. Kim, D. Park, D. Suh, K. Kim, J. Lee, H. Jeon, J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 42-47.
[11] M. Sakaguchi, T. Maebayashi, T. Aizawa, N. Ishibashi, T. Saito. High-dose-rate intracavitary brachytherapy for non-palpable and non-visible recurrent vaginal stump tumors after hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 54-59.
[12] H. Imafuku, Y. Ebina, K. Suzuki, S. Wakahashi, Y. Miyahara, K. Yoshida, H. Yamada. Definitive radiotherapy in elderly patients and patients with locally advanced cervical cancer with complications[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 60-64.
[13] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[14] N. Habib, T. Dennis, G. Centini, L. Bresson, F. Narducci, E. Leblanc. Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 121-125.
[15] R. Tasaka, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. Secondary small cell carcinoma of the endometrium after concurrent chemoradiotherapy for cervical cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 142-144.
No Suggested Reading articles found!